Literature DB >> 23915224

Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphoma.

Elisabet E Manasanch1, Raul Braylan, Maryalice Stetler-Stevenson, Constance Yuan, Verena Gounden, Neha Korde, Nishant Tageja, Manisha Bhutani, Katherine Calvo, Irina Maric, Mark Roschewski, Louis M Staudt, Ola Landgren.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23915224      PMCID： PMC5571753          DOI： 10.3109/10428194.2013.831091

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  6 in total

1.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

2.  MYD88 L265P somatic mutation in IgM MGUS.

Authors:  Ola Landgren; Louis Staudt
Journal:  N Engl J Med       Date:  2012-12-06       Impact factor: 91.245

3.  MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.

Authors:  Steven P Treon; Lian Xu; Guang Yang; Yangsheng Zhou; Xia Liu; Yang Cao; Patricia Sheehy; Robert J Manning; Christopher J Patterson; Christina Tripsas; Luca Arcaini; Geraldine S Pinkus; Scott J Rodig; Aliyah R Sohani; Nancy Lee Harris; Jason M Laramie; Donald A Skifter; Stephen E Lincoln; Zachary R Hunter
Journal:  N Engl J Med       Date:  2012-08-30       Impact factor: 91.245

Review 4.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies.

Authors:  Neha Korde; Sigurdur Y Kristinsson; Ola Landgren
Journal:  Blood       Date:  2011-03-25       Impact factor: 22.113

5.  MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.

Authors:  Lian Xu; Zachary R Hunter; Guang Yang; Yangsheng Zhou; Yang Cao; Xia Liu; Enrica Morra; Alessandra Trojani; Antonino Greco; Luca Arcaini; Marzia Varettoni; Maria Varettoni; Jennifer R Brown; Yu-Tzu Tai; Kenneth C Anderson; Nikhil C Munshi; Christopher J Patterson; Robert J Manning; Christina K Tripsas; Neal I Lindeman; Steven P Treon
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

6.  Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.

Authors:  Marzia Varettoni; Luca Arcaini; Silvia Zibellini; Emanuela Boveri; Sara Rattotti; Roberta Riboni; Alessandro Corso; Ester Orlandi; Maurizio Bonfichi; Manuel Gotti; Cristiana Pascutto; Silvia Mangiacavalli; Giorgio Croci; Valeria Fiaccadori; Lucia Morello; Maria Luisa Guerrera; Marco Paulli; Mario Cazzola
Journal:  Blood       Date:  2013-01-25       Impact factor: 22.113
  6 in total
  2 in total

1.  MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma.

Authors:  Fatima Hamadeh; Stephen P MacNamara; Nadine S Aguilera; Steven H Swerdlow; James R Cook
Journal:  Mod Pathol       Date:  2014-09-12       Impact factor: 7.842

2.  Clonotypic analysis of immunoglobulin heavy chain sequences in patients with Waldenström's macroglobulinemia: correlation with MYD88 L265P somatic mutation status, clinical features, and outcome.

Authors:  Loizos Petrikkos; Marie-Christine Kyrtsonis; Maria Roumelioti; George Georgiou; Anna Efthymiou; Tatiana Tzenou; Panayiotis Panayiotidis
Journal:  Biomed Res Int       Date:  2014-08-14       Impact factor: 3.411
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.